| abstract |
Modified fusion proteins of transferrin and therapeutic proteins or therapeutic peptides containing soluble toxin receptors with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include a transferrin component that is not glycosylated or has reduced glycosylation, has no binding to iron, or has a reduced binding, has no binding or binding to the transferrin receptor. Fusion proteins that are modified to be at least one of reduced are included. |